Clinical Endoscopy

The Korean Society of Gastrointestinal Endoscopy (대한소화기내시경학회)
권호 표지
DOI QR코드

DOI QR Code

Remimazolam, a novel drug, for safe and effective endoscopic sedation

  • Jae Min Lee (Department of Internal Medicine, Korea University Anam Hospital) ;
  • Yehyun Park (Department of Internal Medicine, Ewha Womans University Seoul Hospital) ;
  • Dong Won Ahn (Department Internal Medicine, Seoul National University Boramae Medical Center) ;
  • Jun Kyu Lee (Department of Internal Medicine, Dongguk University Ilsan Hospital) ;
  • Kwang Hyuck Lee (Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University College of Medicine)
  • Received : 2024.02.07
  • Accepted : 2024.05.08
  • Published : 2025.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

Remimazolam is a novel benzodiazepine with unique pharmacokinetic and pharmacodynamic properties, making it an ideal candidate for sedation during endoscopic procedures. Distinguished by its rapid onset and short duration of action, remimazolam offers a safer and more efficient alternative to traditional sedatives, such as midazolam and propofol, with fewer side effects, such as hypotension, bradycardia, and respiratory depression. This article reviews the characteristics of remimazolam and its practical advantages, including ease of use, quick recovery time, and minimal residual sedation, emphasizing its potential to improve patient safety and procedural efficiency in clinical endoscopy settings.

Keywords

References

  1. Hinkelbein J, Lamperti M, Akeson J, et al. European Society of Anaesthesiology and European Board of Anaesthesiology guidelines for procedural sedation and analgesia in adults. Eur J Anaesthesiol 2018;35:6–24. https://doi.org/10.1097/EJA.0000000000000683
  2. Practice guidelines for moderate procedural sedation and analgesia 2018: a report by the American Society of Anesthesiologists Task Force on Moderate Procedural Sedation and Analgesia, the American Association of Oral and Maxillofacial Surgeons, American College of Radiology, American Dental Association, American Society of Dentist Anesthesiologists, and Society of Interventional Radiology. Anesthesiology 2018;128:437–479. https://doi.org/10.1097/ALN.0000000000002043
  3. Brohan J, Goudra BG. The role of GABA receptor agonists in anesthesia and sedation. CNS Drugs 2017;31:845–856. https://doi.org/10.1007/s40263-017-0463-7
  4. ASGE Standards of Practice Committee, Early DS, Lightdale JR, et al. Guidelines for sedation and anesthesia in GI endoscopy. Gastrointest Endosc 2018;87:327–337. https://doi.org/10.1016/j.gie.2017.07.018
  5. Nishizawa T, Yoshida S, Toyoshima O, et al. Risk factors for prolonged hospital stay after endoscopy. Clin Endosc 2021;54:851–856. https://doi.org/10.5946/ce.2020.292
  6. Faigel DO, Baron TH, Goldstein JL, et al. Guidelines for the use of deep sedation and anesthesia for GI endoscopy. Gastrointest Endosc 2002;56:613-617. https://doi.org/10.1016/S0016-5107(02)70104-1
  7. Kilpatrick GJ. Remimazolam: non-clinical and clinical profile of a new sedative/anesthetic agent. Front Pharmacol 2021;12:690875. https://doi.org/10.3389/fphar.2021.690875
  8. Wesolowski AM, Zaccagnino MP, Malapero RJ, et al. Remimazolam: pharmacologic considerations and clinical role in anesthesiology. Pharmacotherapy 2016;36:1021–1027. https://doi.org/10.1002/phar.1806
  9. Lee JM, Park Y, Park JM, et al. New sedatives and analgesic drugs for gastrointestinal endoscopic procedures. Clin Endosc 2022;55:581–587. https://doi.org/10.5946/ce.2021.283
  10. U.S. Food and Drug Administration. BYFAVO (remimazolam) for injection, for intravenous use, CIV Initial U.S. Approval: 2020 [Internet]. U.S. Food and Drug Administration; 2020 [cited 2024 Jan 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212295s002lbl.pdf
  11. European Medicines Agency (EMA). Byfavo (remimazolam): summary of product characteristics [Internet]. EMA; 2021 [cited 2024 Jan 9]. Available from: https://www.ema.europa.eu/en/documents/product-information/byfavo-epar-product-information_en.pdf
  12. Antonik LJ, Goldwater DR, Kilpatrick GJ, et al. A placebo-and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. safety, efficacy, and basic pharmacokinetics. Anesth Analg 2012;115:274–283. https://doi.org/10.1213/ANE.0b013e31823f0c28
  13. Zhou Y, Hu P, Jiang J. Metabolite characterization of a novel sedative drug, remimazolam in human plasma and urine using ultrahigh-performance liquid chromatography coupled with synapt high-definition mass spectrometry. J Pharm Biomed Anal 2017;137:78–83. https://doi.org/10.1016/j.jpba.2017.01.016
  14. Stöhr T, Colin PJ, Ossig J, et al. Pharmacokinetic properties of remimazolam in subjects with hepatic or renal impairment. Br J Anaesth 2021;127:415–423. https://doi.org/10.1016/j.bja.2021.05.027
  15. Rogers WK, McDowell TS. Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures. IDrugs 2010;13:929–937.
  16. Eisenried A, Schüttler J, Lerch M, et al. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers: Part II. Pharmacodynamics of electroencephalogram effects. Anesthesiology 2020;132:652–666. https://doi.org/10.1097/ALN.0000000000003102
  17. Wiltshire HR, Kilpatrick GJ, Tilbrook GS, et al. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. population pharmacokinetic and pharmacodynamic modeling and simulation. Anesth Analg 2012;115:284–296. https://doi.org/10.1213/ANE.0b013e318241f68a
  18. Rex DK, Bhandari R, Desta T, et al. A phase III study evaluating the efficacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopy. Gastrointest Endosc 2018;88:427–437. https://doi.org/10.1016/j.gie.2018.04.2351
  19. Pambianco DJ, Borkett KM, Riff DS, et al. A phase IIb study comparing the safety and efficacy of remimazolam and midazolam in patients undergoing colonoscopy. Gastrointest Endosc 2016;83:984–992. https://doi.org/10.1016/j.gie.2015.08.062
  20. Rex DK, Bhandari R, Lorch DG, et al. Safety and efficacy of remimazolam in high risk colonoscopy: a randomized trial. Dig Liver Dis 2021;53:94–101. https://doi.org/10.1016/j.dld.2020.10.039
  21. Park HJ, Kim BW, Lee JK, et al. 2021 Korean Society of Gastrointestinal Endoscopy clinical practice guidelines for endoscopic sedation. Clin Endosc 2022;55:167–182. https://doi.org/10.5946/ce.2021.282
  22. Tan Y, Ouyang W, Tang Y, et al. Effect of remimazolam tosilate on early cognitive function in elderly patients undergoing upper gastrointestinal endoscopy. J Gastroenterol Hepatol 2022;37:576–583. https://doi.org/10.1111/jgh.15761
  23. Hu B, Jiang K, Shi W, et al. Effect of remimazolam tosilate on respiratory depression in elderly patients undergoing gastroscopy: a multicentered, prospective, and randomized study. Drug Des Devel Ther 2022;16:4151–4159. https://doi.org/10.2147/DDDT.S391147
  24. Kempenaers S, Hansen TG, Van de Velde M. Remimazolam and serious adverse events: a scoping review. Eur J Anaesthesiol 2023;40:841–853. https://doi.org/10.1097/EJA.0000000000001902
  25. Kanno Y, Ohira T, Harada Y, et al. Safety and recipient satisfaction of propofol sedation in outpatient endoscopy: a 24-hour prospective investigation using a questionnaire survey. Clin Endosc 2021;54:340–347. https://doi.org/10.5946/ce.2020.138
  26. Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy, Lichtenstein DR, Jagannath S, et al. Sedation and anesthesia in GI endoscopy. Gastrointest Endosc 2008;68:815–826. https://doi.org/10.1016/j.gie.2008.09.029
  27. Pozin IE, Zabida A, Nadler M, et al. Respiratory complications during recovery from gastrointestinal endoscopies performed by gastroenterologists under moderate sedation. Clin Endosc 2023;56:188–193. https://doi.org/10.5946/ce.2022.033
  28. Lu K, Wei S, Ling W, et al. Remimazolam versus propofol for deep sedation/anaesthesia in upper gastrointestinal endoscopy in elderly patients: a multicenter, randomized controlled trial. J Clin Pharm Ther 2022;47:2230–2236. https://doi.org/10.1111/jcpt.13797
  29. Ye E, Wu K, Ye H, et al. Comparison of 95% effective dose of remimazolam besylate and propofol for gastroscopy sedation on older patients: a single-centre randomized controlled trial. Br J Clin Pharmacol 2023;89:3401–3410. https://doi.org/10.1111/bcp.15839
  30. Ahmer W, Imtiaz S, Alam DM, et al. Remimazolam versus propofol for sedation in gastrointestinal endoscopy and colonoscopy within elderly patients: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 2024;80:493–503. https://doi.org/10.1007/s00228-024-03624-6
  31. Doi M, Morita K, Takeda J, et al. Efficacy and safety of remimazolam versus propofol for general anesthesia: a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial. J Anesth 2020;34:543–553. https://doi.org/10.1007/s00540-020-02788-6
  32. Karavokiros KA, Tsipis GB. Flumazenil: a benzodiazepine antagonist. DICP 1990;24:976–981. https://doi.org/10.1177/106002809002401013
  33. Yamamoto T, Kurabe M, Kamiya Y. Re-sleeping after reversal of remimazolam by flumazenil. J Anesth 2021;35:322. https://doi.org/10.1007/s00540-021-02915-x
  34. Lin OS. Sedation for routine gastrointestinal endoscopic procedures: a review on efficacy, safety, efficiency, cost and satisfaction. Intest Res 2017;15:456–466. https://doi.org/10.5217/ir.2017.15.4.456
  35. Delgado AA, de Moura DT, Ribeiro IB, et al. Propofol vs traditional sedatives for sedation in endoscopy: a systematic review and meta-analysis. World J Gastrointest Endosc 2019;11:573–588. https://doi.org/10.4253/wjge.v11.i12.573
  36. Qiu Y, Gu W, Zhao M, et al. The hemodynamic stability of remimazolam compared with propofol in patients undergoing endoscopic submucosal dissection: a randomized trial. Front Med (Lausanne) 2022;9:938940. https://doi.org/10.3389/fmed.2022.938940
  37. Lee J, Jeong S, Lee DH, et al. Finding the ideal sedative: a non-inferiority study of remimazolam vs propofol in endoscopic retrograde cholangiopancreatography. J Gastroenterol Hepatol 2023;38:2160–2166. https://doi.org/10.1111/jgh.16354